Phase IV

Phase IV studies, commonly termed post-marketing surveillance trials, continue evaluating approved therapeutics in real-world settings, monitoring long-term safety, exploring additional indications, and optimising treatment protocols in diverse patient populations. These studies extend beyond regulatory requirements, generating evidence that enhances clinical understanding and expands therapeutic utility after marketing authorisation.

Unlike earlier clinical phases conducted in controlled environments, Phase IV trials observe medication performance across broader demographics including elderly patients, pregnant women, and individuals with comorbidities often excluded from pre-approval studies. These investigations identify rare adverse events that only emerge with widespread use, assess drug interactions in polypharmacy scenarios, and document effectiveness across varying healthcare settings. Regulatory authorities increasingly mandate Phase IV commitments as approval conditions, particularly for accelerated approvals. Companies strategically design Phase IV programmes to support lifecycle management, demonstrating value in health economic outcomes that strengthen formulary positioning and market access. These studies generate real-world evidence complementing randomised trial data, informing clinical guidelines and supporting label expansions.